Lumos Pharma, Inc. (LUMO) Misses Q4 EPS by 304c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q4 EPS of ($4.18), $3.04 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $2.05 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• IMF chief says global economy weathered Iran war shock well
• Nvidia Q2 preview: a beat is a fail, a blowout is base case
• Intuit (INTU) Tops Q4 EPS by 49c, Beats on Revenue; Offers FY27 Guidance